Brief: Iaso Biotherapeutics And Cabaletta Bio Announce Exclusive License Agreement For Clinically Validated Cd19 Binder
11/10/2022 12:57
Oct 11 (Reuters) - Cabaletta Bio Inc CABA.O :
* IASO BIOTHERAPEUTICS AND CABALETTA BIO ANNOUNCE EXCLUSIVE
WORLDWIDE LICENSE AGREEMENT FOR CLINICALLY VALIDATED CD19 BINDER
* IASO BIOTHERAPEUTICS ENTITLED TO GET UP TO ABOUT $162
MILLION IN
PAYMENTS
* IASO BIOTHERAPEUTICS HAS RIGHT OF FIRST NEGOTIATION TO
DEVELOP &
COMMERCIALIZE CABALETTA'S PRODUCTS USING LICENSED SEQUENCE IN
GREATER CHINA REGION
Source text for Eikon: ID:nPn1BWDDqa
Further company coverage: CABA.O
Recent news on Cabaletta Bio
See all newsBrief: Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Cabaletta Bio, Inc. reports results for the quarter ended June 30 - Earnings Summary
Cabaletta Bio Q2 net loss widens as R&D costs rise
Cabaletta Bio, Inc. expected to post a loss of 37 cents a share - Earnings Preview
Cabaletta Bio Inc expected to post a loss of 37 cents a share - Earnings Preview